Market Research Logo

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

Summary

Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels of inattention, impulsivity, and hyperactivity, either alone or in combination that have a significant social impact through disruptions at school, work, home, and in relationships. The majority of children with the disorder will continue to experience symptoms into adolescence. 30-50% of children diagnosed with ADHD continue to have problems into adulthood resulting in 2-¬5% of adults having ADHD.

Growth is expected in the global ADHD marketplace, despite the market being widely genericized. This will be driven largely by the anticipated launch of assets from the heavily populated ADHD pipeline, as these products offer clinical advantages that will drive strong uptake. Furthermore, the number of drug-treated patients will increase over the forecast period, driven by increased treatment rates throughout the 7MM, particularly in the adult age group.

Highlights

Key Questions Answered

  • The ADHD market has been dominated by stimulant therapy, with only three approved non-stimulant drugs approved that cannot compete with stimulant drugs in terms of efficacy. Due to lack of evidence for long-term safe use of stimulants, non-stimulants are becoming increasingly popular in the 7MM. Both stimulant and non-stimulant therapies are anticipated to reach the market within the forecast period. How will these change the market overall during the forecast period? Will stimulants maintain market dominance in 2024?
  • The current late stage ADHD pipeline is heavily populated, drugs designed to satisfy what GlobalData has identified as unmet needs. Which of these will have the biggest impact on the market? What strategies are developers undertaking to penetrate this crowded market?
  • ADHD is becoming increasingly recognized, particularly n the adult population, leading to increase number in treated patients across the 7MM. How will these changes impact the growth of the future market?
Key Findings
  • The main driver of growth in the ADHD market will be the increase in the number of drug-treated patients, driven by an increase in treatment rates expected to 2024, particularly in the adult age group.
  • Lack of awareness and recognition of ADHD leads to misdiagnosis; this has acted as a barrier to appropriate treatment for ADHD.
  • The arrival of new therapies across the 7MM will increase treatment rates and provide alternative options for many patients, particularly those who have difficulty or who dislike swallowing pills and those who choose non-stimulant therapy.
  • One of the key unmet needs in the ADHD market of additional treatment options will be somewhat satisfied by the emerging pipeline assets during the forecast. Despite the increasingly competitive nature of the ADHD market, lucrative opportunities remain for products that target unmet needs. In addition, providing clinically relevant, head-to-head comparisons is an important consideration for companies developing drugs to treat these patients.
Scope
  • Overview of ADHD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized ADHD market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the ADHD therapeutics market.
  • Pipeline analysis: focus on 13 late-stage pipeline ADHD drugs discussing emerging trends as well as an overview of earlier phase drugs.
  • Analysis of the current and future market competition in the global ADHD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global ADHD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ADHD therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global ADHD therapeutics market from 2014-2024.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification
3.2.1 Predominantly Inattentive Type
3.2.2 Predominantly Hyperactive-Impulsive Type
3.2.3 Combined Type
3.2.4 Other Specified ADHD Type
3.2.5 Unspecified Type
3.2.6 Severity
3.3 Symptoms
3.4 Prognosis
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.3.1 US
4.3.2 5EU
4.3.3 Japan
4.4 Forecast Methodology
4.4.1 Sources Used Tables
4.4.2 Forecast assumptions and methods
4.4.3 Sources Not Used
4.5 Epidemiological Forecast for ADHD (2014-2024)
4.5.1 Diagnosed Prevalent Cases of ADHD
4.5.2 Age-Specific Diagnosed Prevalent Cases of ADHD
4.5.3 Sex-Specific Diagnosed Prevalent Cases of ADHD
4.5.4 Age-Standardized Prevalence of ADHD
4.5.5 Diagnosed Prevalent Cases of ADHD by Subtype
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 Limitations of the Analysis
4.6.3 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.1.1 Diagnosis
5.1.2 Treatment Guidelines and Leading Prescribed Drugs
5.1.3 Clinical Practice
5.2 US
5.3 5EU
5.4 Japan
6 Competitive Assessment
6.1 Overview
6.2 Product Profiles - Amphetamine (Stimulant)
6.2.1 Dextroamphetamine
6.2.2 Desoxyn (methamphetamine)
6.2.3 Adderall XR (Mixed amphetamine Salts)
6.2.4 Vyvanse (lisdexamphetamine dimesylate)
6.2.5 Dyanavel XR (Liquid Amphetamine XR)
6.2.6 Adzenys XR-ODT (Amphetamine Extended Release-Orally Disintegrating Tablet)
6.3 Product Profiles - Methylphenidate (Stimulant)
6.3.1 Ritalin LA
6.3.2 Concerta
6.3.3 Medikinet XL
6.3.4 Metadate CD
6.3.5 Methylin
6.3.6 Focalin
6.3.7 Daytrana
6.3.8 Quillivant XR/Quillichew
6.3.9 Aptensio XR
6.4 Product Profiles - Non-stimulants
6.4.1 Strattera (Atomoxetine Hydrochloride)
6.4.2 Intuniv (Guanfacine Hydrochloride)
6.4.3 Kapvay (Clonidine)
6.4.4 Other Therapeutic Classes
7 Unmet Need and Opportunity Analysis
7.1 Overview
7.2 More Effective, Longer-Lasting, and/or Non-stimulant Treatment Options
7.2.1 Unmet Need
7.2.2 Gap Analysis
7.2.3 Opportunity
7.3 Clinically Relevant, Head-to-Head Comparisons
7.3.1 Unmet Need
7.3.2 Gap Analysis
7.3.3 Opportunity
7.4 Improved Diagnostic Tests
7.4.1 Unmet Need
7.4.2 Gap Analysis
7.4.3 Opportunity
7.5 Education and Recognition of ADHD
7.5.1 Unmet Need
7.5.2 Gap Analysis
7.5.3 Opportunity
7.6 Discontinuation and Long-Term Safety of Stimulants
7.6.1 Unmet Need
7.6.2 Gap Analysis
7.6.3 Opportunity
8 Pipeline Assessment
8.1 Overview
8.2 Clinical Trial Mapping
8.2.1 Clinical Trials by Class
8.3 Overview of Promising Drugs in Clinical Development
8.4 Promising Amphetamine Drugs in Clinical Development
8.4.1 NT-0201 (Liquid Amphetamine XR)
8.4.2 SHP-465 (Triple-Bead Mixed Amphetamine Salts)
8.4.3 HLD-100 (Dextroamphetamine MR)
8.4.4 Amphetamine Transdermal System (Dextroamphetamine)
8.5 Promising Methylphenidate Drugs in Clinical Development
8.5.1 Cotempla XR-ODT (Extended-Release ODT Methylphenidate)
8.5.2 Benjorna (Methylphenidate Hydrochloride MR)
8.6 Promising Non-stimulant Drugs in Clinical Development
8.6.1 SEP-225289 (Dasotraline)
8.6.2 Centanafadine SR
8.6.3 SPN-810 (Molindone Hydrochloride ER)
8.6.4 SPN-812 (Viloxazine Hydrochloride)
8.6.5 Metadoxine ER
8.6.6 Eltoprazine
8.6.7 CM-4612
8.7 Other Drugs in Development
9 Current and Future Players
9.1 Overview
9.2 Trends in Corporate Strategy
9.3 Company Profiles
9.3.1 Shire
9.3.2 Novartis
9.3.3 Janssen
9.3.4 Eli Lilly
9.3.5 Pfizer/Tris Pharma
9.3.6 Highland Therapeutics
10 Market Outlook
10.1 Global Markets
10.1.1 Forecast
10.1.2 Drivers and Barriers - Global Issues
10.2 US
10.2.1 Forecast
10.2.2 Key Events
10.2.3 Drivers and Barriers
10.3 5EU
10.3.1 Forecast
10.3.2 Key Events
10.3.3 Drivers and Barriers
10.4 Japan
10.4.1 Forecast
10.4.2 Key Events
10.4.3 Driver and Barriers
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.4 Forecasting Methodology
11.4.1 Diagnosed ADHD Patients
11.4.2 Percent Drug-Treated Patients
11.4.3 Launch and Patent Expiry Dates
11.4.4 General Pricing Assumptions
11.4.5 Individual Drug Assumptions
11.4.6 Generic Erosion
11.4.7 Pricing of Pipeline Agents
11.5 Primary Research - KOLs Interviewed for This Report
11.6 Primary Research - Prescriber Survey
11.7 About the Authors
11.7.1 Analyst
11.7.2 Therapy Area Director
11.7.3 Epidemiologists
11.7.4 Managing Epidemiologists
11.7.5 Global Director of Therapy Analysis and Epidemiology
11.8 About GlobalData
11.9 Disclaimer
1.1 List of Tables
Table 1: Classification of ADHD According to the DSM-V and ICD-10-CM
Table 2: Symptoms of ADHD
Table 3: Prognosis and Risks Associated with ADHD
Table 4: Risk Factors and Comorbidities for ADHD
Table 5: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD
Table 6: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD by Subtype, Ages 3‒17 Years
Table 7: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD by Subtype, Ages ≥18 Years
Table 8: 7MM, Sources Not Used in Epidemiological Analysis of ADHD
Table 9: 7MM, Diagnosed Prevalent Cases of ADHD, Both Sexes, Ages ≥3 Years, Select Years, 2014-2024
Table 10: 7MM, Age-Specific Diagnosed Prevalent Cases of ADHD, Both Sexes, N (Row%), 2014
Table 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of ADHD, Ages ≥3 Years, N (Row %), 2014
Table 12: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages 3-17 Years, Children and Adolescents, N (Row %), 2014
Table 13: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages ≥18 Years, Adults, N (Row %), 2014
Table 14: Rating Scales Used for ADHD
Table 15: Treatment Guidelines for Disease ADHD
Table 16: Most Prescribed Drugs for ADHD by Class in the Global Markets, 2014
Table 17: Country Profile - US
Table 18: Country Profile - 5EU
Table 19: Country Profile - Japan
Table 20: Leading Treatments for ADHD, 2015
Table 21: Product Profile - Dextroamphetamine
Table 22: Dextroamphetamine SWOT Analysis, 2015
Table 23: Global Sales Forecasts ($m) for Dextroamphetamine, 2014-2024
Table 24: Product Profile - Desoxyn
Table 25: Desoxyn SWOT Analysis, 2015
Table 26: Global Sales Forecasts ($m) for Desoxyn, 2014-2024
Table 27: Product Profile - Adderall XR
Table 28: Adderall XR SWOT Analysis, 2015
Table 29: Global Sales Forecasts ($m) for Adderall XR, 2014-2024
Table 30: Product Profile - Vyvanse
Table 31: Vyvanse SWOT Analysis, 2015
Table 32: Global Sales Forecasts ($m) for Vyvanse, 2014-2024
Table 33: Product Profile - Dyanavel XR
Table 34: Dyanavel SWOT Analysis, 2015
Table 35: Global Sales Forecasts ($m) for Dyanavel XR, 2014-2024
Table 36: Product Profile - Adzenys XR-ODT
Table 37: Adzenys XR-ODT SWOT Analysis, 2015
Table 38: Global Sales Forecasts ($m) for Adzenys XR-ODT, 2014-2024
Table 39: Product Profile - Ritalin LA
Table 40: Ritalin LA SWOT Analysis, 2015
Table 41: Global Sales Forecasts ($m) for Ritalin LA, 2014-2024
Table 42: Product Profile - Concerta
Table 43: Concerta SWOT Analysis, 2015
Table 44: Global Sales Forecasts ($m) for Concerta, 2014-2024
Table 45: Product Profile - Medikinet XL
Table 46: Medikinet SWOT Analysis, 2015
Table 47: Global Sales Forecasts ($m) for Medikinet XL, 2014-2024
Table 48: Product Profile - Metadate CD
Table 49: Incidence of TEAEs in a Pool of 3-4 Week Clinical Trials - Metadate CD
Table 50: Metadate CD SWOT Analysis, 2015
Table 51: Global Sales Forecasts ($m) for Metadate CD, 2014-2024
Table 52: Product Profile - Methylin
Table 53: Methylin SWOT Analysis, 2015
Table 54: Global Sales Forecasts ($m) for Methylin, 2014-2024
Table 55: Product Profile - Focalin
Table 56: TEAEs - Focalin
Table 57: TEAEs - Focalin XR
Table 58: Focalin SWOT Analysis, 2015
Table 59: Global Sales Forecasts ($m) for Focalin and Focalin XR, 2014-2024
Table 60: Product Profile - Daytrana
Table 61: Daytrana SWOT Analysis, 2015
Table 62: Global Sales Forecasts ($m) for Daytrana, 2014-2024
Table 63: Product Profile - Quillivant XR
Table 64: Quillichew Primary Efficacy Result
Table 65: Quillivant XR SWOT Analysis, 2015
Table 66: Global Sales Forecasts ($m) for Quillivant XR/Quillichew, 2014-2024
Table 67: Product Profile - Aptensio XR
Table 68: Summary of the Parallel Group Study - Aptensio XR
Table 69: Aptensio XR SWOT Analysis, 2015
Table 70: Global Sales Forecasts ($m) for Aptensio XR, 2014-2024
Table 71: Product Profile - Strattera
Table 72: Acute and Maintenance Efficacy Studies - Strattera
Table 73: Common TEAEs reported in acute trials in children and adolescents - Strattera
Table 74: Common TEAEs reported in acute trials in adults - Strattera
Table 75: Strattera SWOT Analysis, 2015
Table 76: Global Sales Forecasts ($m) for Strattera, 2014-2024
Table 77: Product Profile - Intuniv
Table 78: Fixed Dose Studies- Intuniv
Table 79: Intuniv SWOT Analysis, 2015
Table 80: Global Sales Forecasts ($m) for Intuniv, 2014-2024
Table 81: Product Profile - Kapvay
Table 82: Kapvay SWOT Analysis, 2015
Table 83: Global Sales Forecasts ($m) for Kapvay, 2014-2024
Table 84: Unmet Need and Opportunity in ADHD
Table 85: Drugs in Development, 2016
Table 86: Comparison of Therapeutic Classes in Development for ADHD, 2014-2024
Table 87: Product Profile - Liquid Amphetamine XR, NT-0201
Table 88: NT-0201 SWOT Analysis, 2015
Table 89: Global Sales Forecasts ($m) for NT-0201, 2014-2024
Table 90: Product Profile - Triple-Bead Mixed Amphetamine Salts (SHP-465)
Table 91: SHP-465 SWOT Analysis, 2015
Table 92: Global Sales Forecasts ($m) for SHP-465, 2014-2024
Table 93: Product Profile - HLD-100
Table 94: HLD-100 SWOT Analysis, 2015
Table 95: Global Sales Forecasts ($m) for HLD-100, 2014-2024
Table 96: Product Profile - Dextroamphetamine Transdermal Patch
Table 97: Dextroamphetamine Transdermal Patch SWOT Analysis, 2015
Table 98: Global Sales Forecasts ($m) for ATS, 2014-2024
Table 99: Product Profile - Cotempla XR-ODT
Table 100: Cotempla XR-ODT SWOT Analysis, 2015
Table 101: Global Sales Forecasts ($m) for Cotempla XR-ODT, 2014-2024
Table 102: Product Profile - Benjorna
Table 103: Benjorna SWOT Analysis, 2015
Table 104: Global Sales Forecasts ($m) for Benjorna, 2014-2024
Table 105: Product Profile - Dasotraline
Table 106: Dasotraline SWOT Analysis, 2015
Table 107: Global Sales Forecasts ($m) for dasotraline, 2014-2024
Table 108: Product Profile - Centanafadine SR
Table 109: Centanafadine SR SWOT Analysis, 2015
Table 110: Global Sales Forecasts ($m) for centanafadine SR, 2014-2024
Table 111: Product Profile - SPN-810
Table 112: SPN-810 SWOT Analysis, 2015
Table 113: Global Sales Forecasts ($m) for SPN-810, 2014-2024
Table 114: Product Profile - Viloxazine
Table 115: Viloxazine SWOT Analysis, 2015
Table 116: Global Sales Forecasts ($m) for Pipeline Viloxazine, 2014-2024
Table 117: Product Profile - Metadoxine ER
Table 118: Metadoxine ER SWOT Analysis, 2015
Table 119: Global Sales Forecasts ($m) for Metadoxine ER, 2014-2024
Table 120: Product Profile - Eltoprazine
Table 121: Eltoprazine SWOT Analysis, 2015
Table 122: Global Sales Forecasts ($m) for Eltoprazine, 2014-2024
Table 123: Product Profile - CM-4612
Table 124: CM-4612 SWOT Analysis, 2015
Table 125: Global Sales Forecasts ($m) for CM-4612, 2014-2024
Table 126: Drugs in Development, 2016
Table 127: Key Companies in the ADHD Market in the 7MM, 2014
Table 128: Shire’s ADHD Portfolio Assessment, 2015
Table 129: Novartis’ ADHD Portfolio Assessment, 2015
Table 130: Janssen’s ADHD Portfolio Assessment, 2015
Table 131: Eli Lilly’s ADHD Portfolio Assessment, 2015
Table 132: Pfizer/Tris Pharma’s ADHD Portfolio Assessment, 2015
Table 133: Highland Therapeutics’ ADHD Portfolio Assessment, 2016
Table 134: Global Sales Forecasts ($m) for ADHD, 2014-2024
Table 135: ADHD Market - Global Drivers and Barriers, 2014‒2024
Table 136: Sales Forecasts ($m) for ADHD in the US, 2014-2024
Table 137: Key Events Impacting Sales for ADHD in the US, 2014-2024
Table 138: ADHD Market - Drivers and Barriers in the US, 2014‒2024
Table 139: Sales Forecasts ($m) for ADHD in the 5EU, 2014-2024
Table 140: Key Events Impacting Sales for ADHD in the 5EU, 2014-2024
Table 141: ADHD Market - Drivers and Barriers in the 5EU, 2014‒2024
Table 142: Sales Forecasts ($m) for ADHD in Japan, 2014-2024
Table 143: Key Events Impacting Sales for ADHD in Japan, 2014-2024
Table 144: ADHD Market - Drivers and Barriers in Japan, 2014‒2024
Table 145: Key ADHD Launch Dates
Table 146: Key ADHD Patent Expiries
Table 147: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country, 2016
1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of ADHD, Both Sexes, Ages ≥3 Years, Selected Years, 2014-2024
Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of ADHD, Both Sexes, 2014
Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of ADHD, Ages ≥3 Years, 2014
Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of ADHD, Ages ≥3 Years, 2014
Figure 5: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages 3-17 Years, Children and Adolescents, N, 2014
Figure 6: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages ≥18 Years, Adults, N, 2014
Figure 7: Treatment Algorithm for ADHD in the 7MM
Figure 8: ADHD Therapeutics - Class of Therapy, 2016
Figure 9: ADHD - Phase II-III Pipeline, 2016
Figure 10: Competitive Assessment of Late-Stage Pipeline Agents in ADHD, 2014-2024
Figure 11: Clinical and Commercial Positioning of NT-0201
Figure 12: Clinical and Commercial Positioning of SHP-465
Figure 13: Clinical and Commercial Positioning of HLD-100
Figure 14: Clinical and Commercial Positioning of ATS
Figure 15: Clinical and Commercial Positioning of Cotempla XR-ODT
Figure 16: Clinical and Commercial Positioning of Benjorna
Figure 17: Clinical and Commercial Positioning of Dasotraline
Figure 18: Clinical and Commercial Positioning of Centanafadine SR
Figure 19: Clinical and Commercial Positioning of SPN-810
Figure 20: Clinical and Commercial Positioning of Viloxazine
Figure 21: Clinical and Commercial Positioning of Metadoxine ER
Figure 22: Clinical and Commercial Positioning of Eltoprazine
Figure 23: Clinical and Commercial Positioning of CM-4612
Figure 24: Global Sales of Branded Products for ADHD by Company, 2014-2024
Figure 25: Company Portfolio Gap Analysis in ADHD, 2014-2024
Figure 26: Shire SWOT Analysis in ADHD, 2014-2024
Figure 27: Novartis SWOT Analysis in ADHD, 2014-2024
Figure 28: Janssen SWOT in ADHD, 2014-2024
Figure 29: Eli Lilly SWOT Analysis in ADHD, 2014-2024
Figure 30: Pfizer/Tris Pharma SWOT Analysis in ADHD, 2014-2024
Figure 31: Highland Therapeutics SWOT Analysis in ADHD, 2014-2024
Figure 32: Global Sales for ADHD by Country, 2014 and 2024
Figure 33: Global Sales for ADHD by Drug Class, 2014 and 2024
Figure 34: Sales for ADHD by Drug Class in the US, 2014 and 2024
Figure 35: Sales for ADHD by Drug Class in the 5EU, 2014 and 2024
Figure 36: Sales for ADHD by Drug Class in Japan, 2014 and 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report